1-2 of 2
Anita Y.M. Kwan
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

HbA1c Reduction in Dulaglutide-Treated Patients Irrespective of Duration of Diabetes, Microvascular Disease, and BMI: A Post Hoc Analysis From the REWIND Trial

Anita Y.M. Kwan, Hertzel C. Gerstein, Jan Basile, Denis Xavier, Juan M. Maldonado, Sohini Raha, Manige Konig
Journal: Diabetes Care
Diabetes Care 2022;45(3):547–554
https://doi.org/10.2337/dc21-1160
Published: 18 January 2022
View article titled, HbA<sub>1c</sub> Reduction in Dulaglutide-Treated Patients Irrespective of Duration of Diabetes, Microvascular Disease, and BMI: A Post Hoc Analysis From the REWIND Trial
Open the PDF for HbA<sub>1c</sub> Reduction in Dulaglutide-Treated Patients Irrespective of Duration of Diabetes, Microvascular Disease, and BMI: A Post Hoc Analysis From the REWIND Trial in another window
Journal Articles

Baseline Factors Associated With Glycemic Control and Weight Loss When Exenatide Twice Daily Is Added to Optimized Insulin Glargine in Patients With Type 2 Diabetes

Julio Rosenstock, MD, Sylvia K. Shenouda, PHD, Richard M. Bergenstal, MD, John B. Buse, MD, Leonard C. Glass, MD, Cory R. Heilmann, PHD, Anita Y.M. Kwan, MS, Leigh A. MacConell, PHD, Byron James Hoogwerf, MD
Journal: Diabetes Care
Diabetes Care 2012;35(5):955–958
https://doi.org/10.2337/dc11-1434
Published: 11 April 2012
View article titled, Baseline Factors Associated With Glycemic Control and Weight Loss When Exenatide Twice Daily Is Added to Optimized Insulin Glargine in Patients With Type 2 Diabetes
Open the PDF for Baseline Factors Associated With Glycemic Control and Weight Loss When Exenatide Twice Daily Is Added to Optimized Insulin Glargine in Patients With Type 2 Diabetes in another window
Includes: Supplementary data